cyc 682 has been researched along with Benign Neoplasms in 5 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (40.00) | 29.6817 |
| 2010's | 3 (60.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Choudhary, AK; Fleming, IN; Green, SR | 1 |
| Kantarjian, H; Liu, X; Plunkett, W | 1 |
| Diaz, I; Muggia, F; Peters, GJ | 1 |
| Braich, TA; Burch, PA; Camoriano, JK; Delaunoit, T; Erlichman, C; Kaur, JS; Kobayash, T; Reid, JM; Rubin, J | 1 |
| Benhadji, K; Calvo, F; Chiao, J; Cvitkovic, E; Faivre, S; Galmarini, CM; Ghoul, A; Green, SR; Le Tourneau, C; Raymond, E; Serova, M | 1 |
1 review(s) available for cyc 682 and Benign Neoplasms
| Article | Year |
|---|---|
Sapacitabine for cancer.
Topics: Animals; Arabinonucleosides; Cell Cycle; Clinical Trials as Topic; Cytosine; DNA Damage; Drug Evaluation, Preclinical; Humans; Neoplasms; Prodrugs; Randomized Controlled Trials as Topic | 2012 |
1 trial(s) available for cyc 682 and Benign Neoplasms
| Article | Year |
|---|---|
A phase I clinical and pharmacokinetic study of CS-682 administered orally in advanced malignant solid tumors.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Arabinonucleosides; Cytosine; Dose-Response Relationship, Drug; Female; Humans; Male; Middle Aged; Neoplasm Staging; Neoplasms | 2006 |
3 other study(ies) available for cyc 682 and Benign Neoplasms
| Article | Year |
|---|---|
Combination of sapacitabine and HDAC inhibitors stimulates cell death in AML and other tumour types.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Arabinonucleosides; Cell Death; Cell Line, Tumor; Cytosine; Female; Histone Deacetylase Inhibitors; Humans; Hydroxamic Acids; Leukemia, Myeloid, Acute; Mice; Mice, Nude; Neoplasms; Vorinostat; Xenograft Model Antitumor Assays | 2010 |
Nucleoside and nucleobase analogs in cancer treatment: not only sapacitabine, but also gemcitabine.
Topics: Animals; Antimetabolites, Antineoplastic; Arabinonucleosides; Cytosine; Deoxycytidine; Gemcitabine; Humans; Neoplasms; Nucleosides | 2012 |
Antiproliferative effects of sapacitabine (CYC682), a novel 2'-deoxycytidine-derivative, in human cancer cells.
Topics: 5'-Nucleotidase; Antineoplastic Agents; Apoptosis; Arabinonucleosides; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Cell Survival; Cisplatin; Cytarabine; Cytosine; Deoxycytidine; Docetaxel; Drug Resistance, Neoplasm; Drug Synergism; Equilibrative Nucleoside Transporter 1; Gemcitabine; Gene Expression Regulation, Neoplastic; HCT116 Cells; HT29 Cells; Humans; Inhibitory Concentration 50; Molecular Structure; Neoplasms; Reverse Transcriptase Polymerase Chain Reaction; Taxoids | 2007 |